LH expands specialty testing, acquisitions and AI initiatives to drive growth, but macro pressures and currency headwinds could weigh on results.

Patients who get blood work through Labcorp can now receive AI-generated plain-language explanations of their results inside ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

OpenAI is expanding into healthcare with ChatGPT, AI tools, hospital partnerships and ChatGPT Health to help patients, ...

The AI juggernaut is all-in on the healthcare industry, launching three new products in the last six months. But it needs to ...

Labcorp Holdings Inc. , a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July ...

DelveInsight's Pharmacogenomic Testing Service Market Insights report provides the current and forecast market analysis, ...

Colorectal cancer is highly preventable when detected early, yet approximately 4 in 10 eligible adults are not up to date with recommended screenings. While at-home tests offer convenience, the ...

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening ...

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered ...

New research, led by scientists from the Seaver Autism Center for Research and Treatment at Mount Sinai and published in ...